Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled double-blind study of belimumab in IgA nephropathy
2017-004366-10Phase 2Unknown
- Sponsor
- University of Leicester
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of belimumab in IgA nephropathy (IgAN), sponsored by University of Leicester. Status: unknown.
02
Drugs
belimumab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2017-004366-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004366-10.